secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2022-07-22T23:59:59+00:00
Accession:  0001558370-22-010916
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech CFO Robyn Hunter resigns; David Jin appointed CFO effective Aug 16
--------------------------------------------------------------------------------

- CFO Robyn Hunter steps down after 11 years to pursue external opportunities; transition support through year-end.
- David Jin, current VP of Corporate Development and interim CEO/CFO of subsidiary Avenue Therapeutics, named CFO.
- Jin previously held roles at Barings, Sorrento Therapeutics, and FBR & Co, involved in over $3.5B in transactions.
- Jin will continue as Head of Corporate Development and is eligible for standard executive compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837022010916/0001558370-22-010916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837022010916/fbio-20220721x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-010916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer